Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
B&G Foods, Inc. (BGS) - free report >>
Intellia Therapeutics, Inc. (NTLA) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
B&G Foods, Inc. (BGS) - free report >>
Intellia Therapeutics, Inc. (NTLA) - free report >>
Image: Bigstock
New Strong Sell Stocks for August 24th
Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:
B&G Foods, Inc. (BGS - Free Report) manufactures, sells, and distributes a portfolio of shelf-stable and frozen foods, and household products. The Zacks Consensus Estimate for its current year earnings has been revised 3.7% downward over the last 30 days.
Fathom Holdings Inc. (FTHM - Free Report) provides cloud-based real estate brokerage services. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.
Intellia Therapeutics, Inc. (NTLA - Free Report) is a genome editing company, focuses on the development of therapeutics. The Zacks Consensus Estimate for its current year earnings has been revised 21.9% downward over the last 30 days.
Level One Bancorp, Inc. provides business and consumer financial services. The Zacks Consensus Estimate for its current year earnings has been revised 9.9% downward over the last 30 days.
Eloxx Pharmaceuticals, Inc. (ELOX - Free Report) is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 79.3% downward over the last 30 days.
View the entire Zacks Rank #5 List.